Archived Facts

Posts Tagged ‘products’

NEW YORK (Reuters Health) – Nearly one in ten U.S. children undergoing spine fusion surgery get injections with bioengineered bone-growth proteins that have not been approved for that use by health regulators, researchers have found.

Related Posts:

(PRWEB) June 19, 2012

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective medical devices, has filed a lawsuit on behalf of a woman who suffered injuries after receiving transvaginal mesh implants. The suit alleges that these products created an unreasonable risk and directly caused her injuries. The lawsuit was filed on June 8th in the U.S. District Court for the Southern District of West Virginia, Charleston Division (Case No. 2:12-cv-01954) and names American Medical System, Inc., Analytic Biosurgical Solutions, Mentor Corporation, Johnson & Johnson, Ethicon, Inc., Coloplast A/S, Coloplast Corporation, Coloplast Manufacturing and other companies who designed, manufactured or marketed the products as Defendants.

According to the Complaint, the Plaintiff, a woman from Columbus, Indiana, was implanted with the Perigee System with IntePro, Apogee System with IntePro and Mentor Aris Trans-Obturator Tape in March 2007 to treat her stress urinary incontinence (SUI) and pelvic organ prolapse (POP), conditions for which the devices are intended and approved. As a result of these defective products, the lawsuit alleges, she has suffered from significant mental and physical pain and suffering, permanent injury, permanent and substantial physical deformity and loss of bodily organs. The suit also states that the Plaintiff has undergone or will undergo one or more corrective surgeries.

The lawsuit also points out that transvaginal mesh devices were approved via the 510(k) process, meaning that they did not require any sort of formal review for approval. The suit thus alleges that transvaginal mesh implants pose dangerous and unreasonable risks due to numerous defects. The complaint further alleges, among other things, that the material used reacts with and abrades human tissues, harbors infections, becomes embedded and is inappropriately designed for use in the female pelvis. The defendants are accused of misrepresenting the products as safe and effective.

In 2008, the U.S. Food and Drug Administration (FDA) issued a Public Health Notification in response to over 1,000 reports of complications linked to transvaginal mesh, noting that the side effects appeared serious, but rare. Reports included erosion, pain, infection, bleeding, pain during intercourse, organ perforation during placement and urinary problems. Last July, the FDA announced that it had received an additional 2,874 adverse reports associated with the devices. This time, the agency stated that the complications are not rare, pointing out that it is unclear whether or not transvaginal mesh provides any benefit over non-mesh procedures and may expose patients to greater risks. [http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm262435.htm

Last September, the FDA's Obstetrics and Gynecology Devices Advisory Panel recommended that transvaginal mesh implants be reclassified from moderate risk to high risk. The new designation would eliminate the products ability to go through the 510(k) process and mandate clinical evidence to supports its safety and efficacy. In January, the FDA asked 33 manufacturers to conduct post market studies assessing the impact of transvaginal mesh on organ damage and other related issues. [fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/UroGynSurgicalMesh/default.htm]

Earlier this month, Johnson & Johnson announced that it would stop selling four transvaginal mesh products, including the Prolift, Prolife + M, TVT Secur and Prosima systems. According to Bloomberg, the devices are expected to be off the market by the first quarter of 2013. The company has also asked the FDA for 120 days to inform its consumers and healthcare professionals about the decision. [bloomberg.com/news/2012-06-04/j-j-tells-judge-it-will-stop-selling-vaginal-mesh-implant.html]

Parker Waichman LLP continues to offer free lawsuit consultations to victims of transvaginal mesh injuries. If you or a loved one experienced complications following POP and SUI surgery with transvaginal mesh, please visit the firm’s transvaginal mesh injury page at yourlawyer.com.

Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

For more information regarding transvaginal mesh lawsuits and Parker Waichman LLP, please visit: yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).

Contact:

Incoming search terms:

Related Posts:

Washington, DC (PRWEB) June 12, 2012

Atlantic Information Services, Inc., publisher of Health Plan Week and AIS’s Health Reform Week, is pleased to announce its June 26 webinar, Health Information Exchanges: Strategies for Building Next-Generation Insurance Products and Payment Models. See webinar details at http://aishealth.com/marketplace/c2m22_062612.

Pressure to develop new payment models and innovative plan designs is rapidly changing the face of health insurance. Health plans that fail to embrace health information exchanges (HIEs) which are a cornerstone of industry reform are likely to be left in the dust. Managing benefits soon will come down to real-time decisions made with clinical data across the spectrum of a patients care. But determining exactly how to incorporate HIEs is a major challenge for health insurers and providers.

Health insurers are beginning to see HIEs as essential tools that can help them build new payment models and forge provider alliances that reduce waste and incent physicians to keep members out of the hospital. Aetna Inc., for example, recently paid $ 500 million to acquire Medicity, a Utah-based HIE vendor.

For insurers, HIEs offer the potential for greater connectivity with network providers. But while HIEs and other efficiency-improving technologies can create value by reducing utilization, such as duplicate tests and unnecessary treatments, such reductions translate to lost revenue for providers, so health plans must tread carefully.

During the webinar, Bradley M. Fluegel, an executive-in-residence at Health Evolution Partners, Charles Kennedy, M.D., chief executive officer of Accountable Care Solutions, and Sherri Zink, vice president of Medical Informatics at BlueCross BlueShield of Tennessee, will provide deep insight into these and other related topics:


How insurers can transition from claims-based data to HIEs when measuring provider quality.
How to use HIEs to build new payment models and forge provider alliances that reduce waste and incent caregivers.
The pros and cons of buying or building an HIE system, or contracting with an existing one.
How companies such as Aetna and UnitedHealth plan to recoup the nearly $ 1 billion theyve invested in HIE firms.
How insurers can use HIEs to integrate financial risk underwriting with clinical care management.
How to use HIEs to complete Healthcare Effectiveness Data and Information Set (HEDIS) requirements.

Visit http://aishealth.com/marketplace/c2m22_062612 for more details and registration information.

About AIS

AIS develops highly targeted news, data and strategies for managers in hospitals, health plans, medical group practices, pharmaceutical companies and other health care organizations. Learn more at http://www.AISHealth.com.







Related Posts:

New York, NY (PRWEB) April 26, 2012

Independence Holding Company (NYSE:IHC) today announced the formation a new company, IHC Specialty Benefits, Inc. (IHC Specialty), which will accelerate IHCs growth into new niche lines of business.

Jeff Smedsrud, chief marketing officer of IHC, will be chief executive officer and president of the new company.

IHC Specialty will develop new health insurance products and services that are expected to be in greater demand as federal health care reform is implemented. The product lines contemplated for expansion include supplemental and ancillary insurance, such as accident, critical illness and pet insurance. A significant amount of products will be marketed directly to consumers through IHCs proprietary technology.

Dave Keller, former senior vice president of sales and marketing for IHC Health Solutions, and Brian Dow, former senior vice president of ecommerce and business development for IHC Health Solutions, are joining Smedsrud at IHC Specialty, along with nine other team members.

We have seasoned executives who are passionate about growing business and capitalizing on market trends. No matter what happens with health care reform, we have entered into a new world of how consumers buy and utilize health-related products. We plan to embrace this new shopping mentality by offering customized products and exchange platforms, said Smedsrud.

The company is partnering with large payers, accountable care organizations, and distributorsboth local and nationalto create product and consumer solutions.

IHC Specialty is a member of The IHC Group, an insurance organization composed of Independence Holding Company (NYSE:IHC), a publicly traded holding company with more than $ 1 billion in assets, and its operating subsidiaries. The IHC Group is composed of affiliated insurance carriers, marketing and administrative companies and agencies committed to providing excellent service and offering competitive health, life, disability, stop-loss, short-term medical, travel and dental insurance products to groups and individuals. The IHC Group has approximately $ 600 million in annual premium and fees.

Find out more information about IHC Specialty, contact Dave Keller at dave(dot)keller(at)ihcgroup(dot)com.







Incoming search terms:

Related Posts:

Androzene 11/2015 boost energy stamina performance enhancer

$49.00 (8 Bids)
End Date: Tuesday Jul-22-2014 17:29:27 PDT
Bid now | Add to watch list

Medical Sphygmomanometer Gauge & Rubber Adjustable Pump Bulb Assembly
$5.00 (0 Bids)
End Date: Tuesday Jul-22-2014 17:31:39 PDT
Bid now | Add to watch list

NEW TENS 7000 Digital Back Pain Relief System Unit For Muscle & Joint Aches OTC
$37.94
End Date: Wednesday Aug-20-2014 20:19:28 PDT
Buy It Now for only: $37.94
Buy It Now | Add to watch list

Related Posts:

Jason Natural Products Hand & Body Lotion Cranberry, Cranberry 8 OZ

  • JASON NATURAL PRODUCTS Hand/Body Lotion Cranberry Canneberge 8 OZ

Hand/Body Lotion Cranberry Canneberge 8 oz Cranberry Fun Fact: The cranberry is one of only a handful of fruits native to North America – the Concord grape and blueberry being the others. Dutch and German settlers in Massachusetts invented the name “crane berry,” Because the vine blossoms looked like the neck, head and bill of a crane. JASON Cranberry Hand and Body Lotion combines Antioxidants Green Tea, Vitamin E and Cranberry Oil to nourish skin and revitalize the body. Avocado Oil keeps skin soft, supple and toned. * Mineral Oil, Petrolatum Free * No Animal By-Products * Paraben Free * No Animal Testing UPC: 078522044666 Aqua (Purified Water), Aloe Barbadensis (Aloe Vera) Leaf Gel*, Vegetable Caprylic/Capric Triglyceride, Glyceryl Stearate SE, Vegetable Glycerin, Dimethicone, Ethylhexl Palmitate, Helianthus Annuus (Sunflower/ Toumesol) Seed Oil*, Stearyl Alcohol, Cetyl Alcohol, Vaccinium Macrocapon (Cranberry) Seed Oil, Natural Tocopheryl Acetate (Vit. E), Persea Gratissima (Avocado) Oil, Chamomilla Recutita (Matricaria) Extract, Camellia Sinensis (Green Tea) Leaf Extract, Rosa Canina (Rose Hips) Fruit Extract Ascophyllum Nodosum (Brown Algae) Extract, Aniba Rosaeodora (Rosewood) Wood Oil, Eugenia Caryophyllus (Clove) Leaf Oil, Allantoin, Panthenol (Vit. B5), Hydroxyethylcellulose, Carbomer, Phenoxyethanol, Potassium Hydroxide, Sodium Benzoate,Potassium Sorbate, Glycereth-2 Cocoate, Benzoic Acid, Fragrance Oil Blend. *Certified Organic Jason Natural

List Price: $ 8.45

Price: $ 6.96

Related Posts:

Smead Products – Smead – Antimicrobial Two-Pocket Portfolio, Embossed Leather Grain 11-Pt Stock, Blue – Sold As 1 Box – Treated with nontoxic SilverCoTM to fight the growth of bacteria, mold, fungus and mildew. – Acid-free, archival quality makes it safe for long-term storage of documents, records, photos. – Keeps hard copy, media and contact information together. – Ideal for offices and healthcare facilities. -

  • Treated with nontoxic SilverCoTM to fight the growth of bacteria, mold, fungus and mildew.
  • Acid-free, archival quality makes it safe for long-term storage of documents, records, photos.
  • Keeps hard copy, media and contact information together.
  • Ideal for offices and healthcare facilities.

Smead – Antimicrobial Two-Pocket Portfolio, Embossed Leather Grain 11-Pt Stock, Blue – Sold As 1 Box

Treated with nontoxic SilverCoTM to fight the growth of bacteria, mold, fungus and mildew. Acid-free, archival quality makes it safe for long-term storage of documents, records, photos. Keeps 11x 8 1/2 hard copies, media and contact information together. Ideal for offices and healthcare facilities. 11 pt. stock with embossed leatherette grain. Die-cut business card holder on inside front pocket. Front Cover Color(s): Blue; Back Cover Color(s): Blue; Sheet Size: 11 x 8 1/2; Capacity (text): N/A.

  • Treated with nontoxic SilverCoTM to fight the growth of bacteria, mold, fungus and mildew.
  • Acid-free, archival quality makes it safe for long-term storage of documents, records, photos.
  • Keeps hard copy, media and contact information together.
  • Ideal for offices and healthcare facilities.


  • List Price: $ 27.25

    Price: $ 20.19

    Related Posts:

  • Fargo, ND (PRWEB) April 13, 2012

    Nattokinase is an enzyme extracted from natto, a traditional dish from Japan made of fermented soybeans. The enzyme harvested is fibrinolytic and is shown to promote healthy blood flow to support cardiovascular and circulatory health. Swanson Ultra Maximum Strength Nattokinase features the patented NSK-SD

    Incoming search terms:

    Related Posts:

    The Food and Drug Administration said Wednesday that antiseptic products made by Triad Group and H&P Industries were seized to prevent the distribution of products that might be contaminated and pose a health risk.

    Related Posts:

    Johnson & Johnson on Thursday recalled several types of Rolaids antacids in the U.S. because of reports of metal and wood particles in the products.
    All News, Video and Posts related to SECTOR: Health Care

    Related Posts: